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Abstract 
Multifactorial risk factors such as HIV/HCV co-infection and antiretroviral therapy (ARV) have 
been associated with osteoporosis in HIV+ women. We retrospectively analysed which known risk 
factors were associated with the diagnosis of osteoporosis, according to the WHO definition, in 
HIV positive women who were followed-up at the AIDS Centre of the University of Palermo, Italy 
between January 2011 and December 2014.  
Twenty-one HIV+ women with osteoporosis (13 HIV+ mono-infected and 8 HIV/HCV co-infected 
females) who underwent dual-energy X-ray absorptiometry (DXA) and liver stiffness assessment 
were included in the study.  
No significant differences between the HIV and HIV/HCV group were found regarding liver 
stiffness and lumbar/femoral osteoporosis scores. In a univariate analysis, we observed a positive 
linear correlation between LBD score (Lumbar Bone Density) with pre-fractures (p-value = 
0.0082), smoke (p-value = 0.0008), alcohol (p-value < 0.0001) and ARV exposure score (p-value = 
0.0039), while there were no significant negative linear correlations. In multivariate analysis, pre-
fractures, smoke and alcohol were positive predictors of LBD score, while previous antiretroviral 
therapy (ARV) (years) score was a negative predictor compared to others. Univariate analysis 
showed a positive linear correlation between FDB (Femoral Bone Density) with smoke (p-value = 
0.0303) and alcohol (p-value = 0.0050), while there were no significant negative linear 
correlations. In multivariate analysis, alcohol was a positive predictor of FDB score compared to 
others, while ARV score was a negative predictor compared to others.  
This preliminary study suggests that other factors besides ARV score and liver fibrosis may affect 
the skeletal system in osteoporotic women with HIV infection. Some of these factors, such as 
alcohol and smoking, are modifiable. Additional research into impact on osteoporosis in HIV 
women with osteoporosis is required. 
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Introduction 
Clinical data accumulated over the past two 
decades attest to a significant decline in bone 
mineral density (BMD) in patients infected by 
HIV, which does not remit but may actually 
intensify with anti-retroviral therapy (ART). 
Several studies show that prevalence of 
osteoporosis is more than three times higher in 
HIV-infected patients than in HIV-uninfected 
controls [1-3].  
Recent studies have identified a high prevalence 
of low BMD and osteoporosis among 
predominately Caucasian HIV infected women 
with or without chronic hepatitis [4,5]. 
Much effort has been made to identify the 
numerous multifactorial mechanisms that may be 
involved in skeletal disorders in the HIV setting 
[6-8,30]. In addition to the traditional osteoporosis 
risk factors that may be more prevalent in HIV-
infected patients, such as vitamin D deficiency, 
low body weight, lifestyle risk factors 6,9 
(alcohol consumption, smoking, corticosteroid use 
and drug addiction), HIV infection and chronic 
pro-inflammatory status may play a role in 
decreasing bone mineral density (BMD). Also 
aging, hepatitis co-infections and other HIV-
related infections, antiretroviral therapy (ARV) 
[26-29] and serotonine use in patients affected by 
panic disorder have been associated with skeletal 
disorders and a greater risk of osteoporosis [6-
9,25], and consequent common associated 
pathologies, such as multiple exostoses and 
osteochondral lesions of the talus with edema, 
conditioning quality of life [22-24]. 
Hepatitis C virus (HCV) infection is a major 
health problem in the HIV-infected population 
[10-14]. A recent systematic review and meta-
analysis suggests that HIV/HCV co-infection is 
associated with a greater risk of osteoporosis than 
HIV mono-infection [13], although many 
divergences exist regarding osteoporosis 
prevalence in co-infected patients, with values 
ranging from 5-45%. Moreover, there is some 
debate over whether liver disease severity may 
indeed have a relevant role in increasing the risk 
of osteoporosis in co-infection [12-14]. 
In this study we describe the characteristics of 
both HIV mono-infected and HIV/HCV co-
infected women with osteoporosis, and we 
analyze risk factors for decreased bone mineral 
density (BMD). We investigate which potential 
metabolic, lifestyle and/or HIV-related risk factors 
are associated with decreased BMD, and we 
report a statistical analysis between the two 
groups to ascertain whether bone loss is more 
prevalent in HIV/HCV co-infected patients. 
Materials and Methods  
Data on patients who were followed up at the 
AIDS Center of the “Paolo Giaccone” University 
Hospital in Palermo, Italy, in the day care or 
outpatient facility between January 2011 and May 
2013 were extracted from the hospital’s medical 
record database as previously reported 15. 
We gathered clinical documentation on 21 HIV-
positive women diagnosed with osteoporosis. 
Osteoporosis was diagnosed when either femoral 
neck or lumbar spine DXA T-scores were less 
than -2.5, as recommended by the World Health 
Organization (WHO) and the National 
Osteoporosis Foundation [16,17]. The following 
data were collected and entered into a specially 
designed database: (a) demographic and clinical 
characteristics of the patients: age, gender, 
geographic origin (namely the patient’s 
geographical origin stated in a document certified 
by the Italian institutions), lifestyle habits 
(including educational level, drug abuse history, 
sexual behavior), body mass index (BMI), 
comorbidities such as HCV co-infection, 
osteoporosis biomarker, diabetes and 
hypertension; (b) current CD4
+
 T lymphocyte 
counts (cells/µL) determined by flow cytometry, 
and HIV RNA viral load (VL) measured in 
plasma by reverse transcriptase polymerase chain 
reaction (Roche Amplicor; lower limit of 
quantitation 20 copies/mL, 1.3 log10) as 
previously reported 5,6; and (c) variables related 
to ART, namely date of ART initiation, total time 
on ART, antiretroviral (ARV) drugs received and 
degree of adherence. These data were obtained 
from medical records and previously published 
investigations 6,12,36. All patients except the 
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treatment-naïve subjects had started ART during 
previous inpatient stays. None of the migrants 
enrolled in the study had a general practitioner 
(GP). 
Laboratory methods 
CD4+ T-cell count (most recent value and 
nadir) and plasma HIV-RNA levels of all the HIV 
patients were assessed as previously reported 
[6,15]. Serum bone alkaline phosphatase, 25-
hydroxyvitamin D, phosphorus and calcium levels 
were obtained for both HIV-infected cases and 
un-infected controls. Vitamin D assessment was 
performed in the sunnier months from April 
through October, since we know that vitamin D 
formation is not possible or is inadequate [6] 
during the less sunny months due to Italy’s 
latitude. 
Bone mineral density assessment 
For both HIV-infected cases and uninfected 
controls, BMD was assessed at baseline by DXA, 
using a QDR Discovery Hologic DXA in the 
femoral neck and DXA in the lumbar spine by 
total body DXA [5,6]. For each scan, BMD and T-
scores were recorded. T-scores compare BMD 
with the mean of a healthy young (age 20–30 
years) reference population, matched for sex and 
race, and were expressed as the number of 
standard deviations above or below the reference 
mean. Osteoporosis was diagnosed when either 
femoral neck or lumbar spine DXA T-scores were 
less than -2.5, as recommended by the World 
Health Organization (WHO) and the National 
Osteoporosis Foundation [16,17].  
Liver fibrosis assessment  
Transient elastography (FibroScan®; EchoSens, 
Paris, France), which assesses liver fibrosis by 
measuring liver stiffness, was performed on the 
HIV/HCV co-infected patients. Details of the 
technical background and examination procedure 
have previously been described [18]. Liver 
cirrhosis was defined as liver stiffness ≥ 12.5 kPa 
according to the standard definition [10,11].  
Statistical analysis 
Statistical analysis was performed by Matlab 
statistical toolbox version 2008 (MathWorks, 
Natick, MA, USA) for Windows at 32 bit, on a 
random sample of 21 females with osteoporosis, 
aged from 37-59 years, with mean 47.62 y.o. and 
standard deviation 8.32 y.o.  
In addition, we considered two subgroups, one 
with patients who tested positive for HIV only, 
and the other with people who tested positive for 
HIV/HCV co-infection.  
Data were presented as number and percentage 
for categorical variables, and continuous data 
were expressed as mean ± standard deviation 
(SD), unless otherwise specified. The 2 test with 
Yates correction and Fisher's exact test were 
performed to evaluate significant differences of 
proportions or percentages between the two 
groups. In particular, Fisher's exact test was used 
when the 2 test was not appropriate. 
We performed the one-way ANOVA test to 
evaluate significant differences between mean 
scores for the HIV and HIV/HCV group.  
Finally, univariate and multivariate linear 
correlation analysis was performed, where the test 
on Pearson’s linear correlation coefficient R was 
performed with t-Student test, under null 
hypothesis of Pearson’s linear correlation 
coefficient R = 0.  
For this step we considered LBD score (Lumbar 
Bone Density) and FDB score (Femoral Bone 
Density) as dependent variables, and pre-
fractures, smoke, alcohol and previous 
antiretroviral therapy (ARV) (years) as 
independent variables. We did not consider age, 
BMI and menopause among the independent 
variables as their impact on osteoporosis is 
already well noted. In particular, we considered 
continuous experimental probability distribution 
for dichotomous variables as follows: 
 for smoke we assigned 1 to patients who 
smoked and 0 to non smokers;  
 for alcohol, we assigned 1 to patients who 
drank alcohol and 0 to those who didn’t;   
 for pre-fractures we assigned 1 to the 
presence and 0 to the absence of pre-
fractures;  
 for infected, we assigned 0 to HIV infected 
patients and 1 to HIV/HCV co-infected 
patients; 
 for assumption of drugs we assigned 1 for 
yes and 0 for no. 
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We considered all statistical tests with p-value < 
0.05 to be significant. 
In accordance with international standards, a T-
score of TR or TF  -2.5 indicated that the patient 
had osteoporosis. 
Results 
We consecutively enrolled 21 HIV-positive 
women (46.92 y.o. ± 3.97 SD): 13 HIV female 
patients aged 38-53, mean 46.92 y.o. and standard 
deviation (SD) 3.97 y.o., and 8 HIV/HCV female 
patients aged 37-79, mean 48.75 y.o. and standard 
deviation (SD) 12.42 y.o.. Table 1 shows the 
characteristics of these women.  
Comparative analysis of the two groups did not 
show any statistical difference between HIV 
mono- and HIV/HCV co-infected osteoporotic 
women.  
As reported in Table 2, univariate analysis 
revealed a positive linear correlation between 
LBD score with pre-fractures (p-value = 0.0082), 
smoke (p-value = 0.0008), alcohol (p-value < 
0.0001) and previous antiretroviral therapy 
(ARV) (years) (p-value = 0.0039), while there 
were no significant negative linear correlations.  
Multivariate analysis showed that pre-fractures, 
smoke and alcohol were positive predictors of 
LBD, while previous antiretroviral therapy 
(ARV) (years) was a negative predictor compared 
to others. In others words, the presence of pre-
fractures, smoke or alcohol implied a higher LBD 
score, i.e. the patients’ osteoporosis score tended 
towards zero, and the assumption of ARV drugs 
indicated a higher likelihood of osteoporosis 
compared to others.  
The results of univariate analysis reported in 
Table 2 show a positive linear correlation between 
FBD score with smoke (p-value = 0.0303) and 
alcohol (p-value = 0.0050), while there were no 
significant negative linear correlations. 
Multivariate analysis revealed alcohol to be a 
positive predictor of FBD compared to others, 
while previous ARV was a negative predictor 
compared to others. In other words, the presence 
of smoke or alcohol implied a higher FBD score, 
i.e. the patients’ osteoporosis score showed a 
tendency towards zero and the assumption of ARV 
drugs indicated a higher likelihood of 
osteoporosis compared to others. 
Finally, this preliminary study identified no 
correlation between (mono/co)-infection and LBD 
or FBD score.  
Univariate analysis showed a positive linear 
correlation between LBD score with pre-fractures 
(p-value = 0.0082), smoke (p-value = 0.0008), 
alcohol (p-value < 0.0001) and previous 
antiretroviral therapy (ARV) (years) (p-value = 
0.0039), while there were no significant negative 
linear correlations. In multivariate analysis pre-
fractures, smoke and alcohol were positive 
predictors of LBD, while previous antiretroviral 
therapy (ARV) (years) was a negative predictor 
compared to others. In others words, the presence 
of pre-fractures, smoke or alcohol implied a 
higher LBD score. 
Univariate analysis showed a positive linear 
correlation between FBD score with smoke (p-
value = 0.0303) and alcohol (p-value = 0.0050), 
while there were no significant negative linear 
correlations. In multivariate analysis, alcohol was 
a positive predictor of FBD compared to others, 
while previous ARV was a negative predictor 
compared to others. In others words, the presence 
of smoke or alcohol implied a higher FBD score. 
Discussion  
The authors selected a group of HIV-infected 
patients with osteoporosis to identify which 
factors may influence progression to low bone 
mineral density, in women in particular.  
Although our study involved a small group of 
women, we found no difference in osteoporosis 
score for HIV mono-infected women and those 
co-infected with the hepatitis C virus. 
Vincent Lo Re demonstrated that, compared to 
healthy reference patients, HIV/HCV co-infected 
women had decreased tibial trabecular volumetric 
BMD, diminished cortical dimensions, and 
significant endocortical bone loss 4. 
In a previous study, the authors found that 
extent of liver fibrosis, measured by transient 
elastography, was an independent predictor of 
bone loss in HIV/HCV co-infection, confirming 
what we found in our own study 5. 
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Valentina Li Vecchi et al. 5 found that when 
patients were stratified by sex, a negative 
correlation between BMD and severity of liver 
fibrosis applied to co-infected women only, 
suggesting that other factors (i.e. sexual 
hormones) may affect the skeletal system in 
HIV/HCV co-infection more than liver fibrosis.  
These observations appear to be in line with 
what we observed and have reported in this paper, 
where other factors such as previous fracture, 
alcohol and smoking are significantly prevalent 
risk factors in women with osteoporosis. 
In particular, multivariate analysis showed that 
pre-fractures, smoke and alcohol were positive 
predictors of LBD score. It also confirmed that the 
risk factor alcohol is a positive predictor for FDB 
score compared to others. 
The risk factor previous antiretroviral therapy 
(ARV) (years) score was a negative predictor for 
both LBD score and FDB score compared to 
others. 
In a previous study the authors found that, 
regarding antiretroviral drugs, the use of protease 
inhibitors (PI) was a risk factor for 
osteopenia/osteoporosis.   
Due to the small number of subjects enrolled in 
this study, we did not establish which group of 
ARV drugs is correlated with osteoporosis score, 
therefore we maintain that number of years of 
ARV treatment is not a risk factor for 
osteoporosis.  
Among the various factors shown to affect 
osteoporosis, it is no surprise to us that our study, 
like others, has confirmed that previous fracture, 
alcohol abuse and smoking are strong and relevant 
factors that affect osteoporosis in women. These 
factors have also been described for men.   
Alcohol use was recently correlated with low 
bone mineral density in adults with HIV infection. 
This risk factor is one of the modifiable ones for 
both HIV disease progression and low BMD 19.  
Smoking is another lifestyle risk factor. In vitro 
studies recently demonstrated that nicotine has a 
negative effect on osteoclastogenesis 19,20. 
Costa-Rodrigues J 20 published a manuscript 
in which cigarette smoke is associated with 
pathological weakening of bone tissue, and is 
considered an important playmaker in conditions 
such as osteoporosis and periodontal bone loss. In 
addition, it is also associated with an increased 
risk of failure in bone regeneration strategies.  
This knowledge opens up new horizons for the 
HIV positive patient, in whom smoking is often a 
risk factor, especially in HIV positive women 
21. 
Smoking, therefore, is a candidate risk factor 
not only for cardiovascular disease or tumours, 
but also for osteoporosis.   
Regarding pre-fractures, complications of 
pertussis including rib fracture were recently 
reported in an adult with osteoporosis 31,32,39.  
As far as surveillance of vaccination coverage 
among adult populations is concerned, the authors 
encourage the identification of adults who do not 
have a regular provider or insurance of 
vaccination against acellular pertussis, and against 
other infectious diseases such as zoonoses, 
leishmaniasis and tuberculosis 33-35,27,38, 
40,41. 
In conclusion, our study highlights some risk 
factors correlated with osteoporosis in women 
with osteoporosis, such as alcohol and smoking. 
These risk factors are modifiable, and this 
confirms how education programmes that promote 
a different lifestyle could mitigate the impact of 
some HIV-related comorbidities. 
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Table 1. Characteristics of patients with osteoporosis by HIV and HIV/HCV group. In addition, in 
the last column, we report a statistical analysis between the HIV and HIV/HCV group 
 
Characteristics HIV (OP) HIV/HCV (OP) Statistical analysis: p-value 
% patients 61.90 (13/21) 38.10 (8/21) 0.217 (CY) 
Age 46.92 ± 3.97 48.75 ± 12.42 0.624 (A) 
Pre-fractures 38.46 (5/13) 37.50 (3/8) 1.00 (F) 
Menopause 38.46 (5/13) 37.50 (3/8) 1.00 (F) 
Smoke 76.92 (10/13) 62.50 (5/8) 0.631 (F) 
Previous antiretroviral therapy 
(ARV)  (years)  
61.54 (8/13) 50.00 (4/8) 0.673 (F) 
Alcohol 38.46 (5/13) 50.00 (4/8) 0.673 (F) 
Nadir CD4+ 84.62 (11/13) 37.50 (3/8) 0.056 (F) 
LBD -3.38 ± 0.35 -3.56 ± 0.73 0.453 (A) 
FBD -2.23 ± 0.36 -2.39 ± 0.34 0.326 (A) 
Undetectable HIV-RNA 76.92 (10/13) 42.86 (3/8) 0.164 (F) 
Genotype 
    Type 1  
    Type 2 
    Type 3 
    Type 4 
 
84.62 (11/13) 
0.00 (0/13) 
7.69 (1/13) 
7.69 (1/13) 
 
100.00 (8/8) 
0.00 (0/8) 
0.00 (0/8) 
0.00 (0/8) 
 
0.505 (F) 
1.00 (F) 
1.00 (F) 
1.00 (F) 
Liver stiffness (kPa) 14.02 ± 13.47 10.43 ± 2.27 0.468 (A) 
BMI  23.10 ± 4.10 21.70 ± 4.77 0.483 (A) 
Total 13 8  
(A) = one-way Anova test; (CY) = Chi-square test with Yates continuity correction; (F) = Fisher's exact test; 
* = significant 
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Table 2. Univariate and multivariate linear correlation analysis between LBD score (Lumbar Bone 
Density) and FDB score (Femoral Bone Density) as dependent variables and pre-fractures, 
menopause, smoke, alcohol, infected and drugs as independent variables. 
 
Dependent variable / independent variable Univariate analysis Multivariate analysis 
 R (p-value) Multiple linear correlation coefficient: 0.877  
LBD / Pre-fractures 0.561 (0.0082) * R_partial: 0.511  p-value = 0.0362* 
LBD / Smoke 0.675 (0.0008)* 
R_partial: 0.492  p-value = 0.0448 * 
LBD / Alcohol 0.792 (<0.0001)* R_partial: 0.670  p-value = 0.0032 * 
LBD / Previous antiretroviral therapy (ARV)  
(years) 0.602 (0.0039) * 
R_partial: -0.587  p-value = 0.0133 *  
LBD / Infected -0.253 (0.269) 
R_partial: 0.430  p-value = 0.0851 
 R (p-value) Multiple linear correlation coefficient: 0.771  
FBD / Pre-fractures 0.169 (0.465) 
R_partial: 0.214  p-value = 0.409 
FBD / Smoke 0.473 (0.0303)* 
R_partial: 0.472  p-value = 0.056 
FBD / Alcohol 0.588 (0.0050) * 
R_partial: 0.561  p-value = 0.0191 * 
FBD / ARV 0.276 (0.226) 
R_partial: -0.556  p-value = 0.0204 * 
FBD / Infected -0.298 (0.190) 
R_partial: 0.257  p-value = 0.320 
* = significance test; R = Pearson’s linear correlation coefficient; R_partial = the partial correlation coefficient is the 
coefficient of correlation of the variable with the dependent variable, adjusted for the effect of the other variables in the 
model 
 
